Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis

Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis

Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis

Inclusion Criteria:

• Patients with remitting multiple sclerosis according to mac Donald criteria
• aggressive remitting multiple sclerosis according to following criteria:
• 2 or less disabling relapse during the 12 months before inclusion
• 1 or more
• EDSS between 2 and 5
• aged less or equal to 40 years old for the women
• effective contraception

Exclusion Criteria:

• patients less than 18 years old